CEACAM5 and pancreatic neoplasm: Combined detection of biomarkers such as MUC5AC and DUPAN-2 can improve the limitations of false negatives of CA19–9 in Lewis-negative individuals (49), while the combined detection of CEA and CA125 aids in the differential diagnosis of pancreatic cancer and other gastrointestinal tumors (50, 51).